Akagera Medicines, Inc的封面图片
Akagera Medicines, Inc

Akagera Medicines, Inc

生物技术

Boston，MA 412 位关注者

Targeting Tuberculosis with Liposomal Nanotherapeutics

关注

关于我们

Akagera Medicines is developing novel liposomal formulations of antibacterial drugs to treat tuberculosis. The company was founded in 2018 in Kigali, Rwanda. It is well-funded, majority-owned by the people of Rwanda, incorporated as a Delaware corporation, and has laboratories in Boston and San Francisco. Board members and advisors include Ambassador Dr. Albrecht Conze, Dr. Paul Farmer, Dr. Donald Kaberuka, and Dr. Anne Lenaerts. Akagera Medicines intends (if toxicology and Proof of Concept efficacy studies go as anticipated) to begin IND-enabling studies in Q4 2020. The moral purpose of Akagera Medicines is to create medicines that lead to a world free of tuberculosis (TB), humankind’s greatest killer. This means improving efficacy, shortening the duration of treatment, optimizing drug/drug interaction, eliminating toxicity, and lowering the costs to patients and to society. Our Goals ? to initiate clinical trials in humans in 2022; ? to reduce the global incidence of TB deaths by 80% in the next decade; ? to eradicate the multi-drug resistant (MDR) form of TB; ? to explore the high probability that Akagera Medicines' approach will work to create treatments and vaccines in other infectious diseases like MRSA, Malaria, and HIV; ? and to ensure that those treatments could be created, tested, and manufactured in the heart of Africa.

网站
https://www.akageramedicines.com/
所属行业
生物技术
规模
2-10 人
总部
Boston，MA
类型
私人持股

地点

Akagera Medicines, Inc员工

查看全部员工

动态

  • Akagera Medicines, Inc转发了

    Prepare for a celestial journey through the realm of clinical research as we delve into the mysteries of the human immune system and the transformative potential of vaccines - celebrating WORLD IMMUNIZATION WEEK! Allow us to introduce our Stellar Speakers: ??? Meet Dr.?Daryl Drummond, Ph.D: He is currently the Founder, Chief Scientific Officer, and Senior Vice President of?Akagera Medicines, Inc, with 30 years of experience in the research and development of liposomal and lipidic nanoparticle (LNP) based therapeutics and vaccines. Akagera Medicines, Inc: This innovative company is pioneering novel liposomal formulations of antibacterial drugs for tackling tuberculosis. Additionally, they're blazing trials in the realm of mRNA vaccines, targeting neglected infectious diseases like tuberculosis, Lassa Fever, and HIV. ??? Presenting Dr.?Elana van Brakel: She is a distinguished Medical Director at?IAVI?with their head offices in New York, USA, leveraging over two decades of experience in clinical development and infectious diseases. About?IAVI: IAVI is a beacon of hope, translating scientific breakthroughs into accessible public health solutions worldwide. Their focus on developing vaccines and antibodies spans critical areas such as HIV, tuberculosis, and emerging infectious diseases. ?? Topic: Clinical Research and the life-saving power of vaccines ??? Save the date: April 25th, ? Time: 16:00 - 17:00 GMT

  • Prepare for a celestial journey through the realm of clinical research as we delve into the mysteries of the human immune system and the transformative potential of vaccines - celebrating WORLD IMMUNIZATION WEEK! Allow us to introduce our Stellar Speakers: ??? Meet Dr.?Daryl Drummond, Ph.D: He is currently the Founder, Chief Scientific Officer, and Senior Vice President of?Akagera Medicines, Inc, with 30 years of experience in the research and development of liposomal and lipidic nanoparticle (LNP) based therapeutics and vaccines. Akagera Medicines, Inc: This innovative company is pioneering novel liposomal formulations of antibacterial drugs for tackling tuberculosis. Additionally, they're blazing trials in the realm of mRNA vaccines, targeting neglected infectious diseases like tuberculosis, Lassa Fever, and HIV. ??? Presenting Dr.?Elana van Brakel: She is a distinguished Medical Director at?IAVI?with their head offices in New York, USA, leveraging over two decades of experience in clinical development and infectious diseases. About?IAVI: IAVI is a beacon of hope, translating scientific breakthroughs into accessible public health solutions worldwide. Their focus on developing vaccines and antibodies spans critical areas such as HIV, tuberculosis, and emerging infectious diseases. ?? Topic: Clinical Research and the life-saving power of vaccines ??? Save the date: April 25th, ? Time: 16:00 - 17:00 GMT

相似主页

查看职位